• Yuan Ji, Jennifer M Skierka, Joseph H Blommel, Brenda E Moore, Douglas L VanCuyk, Jamie K Bruflat, Lisa M Peterson, Tamra L Veldhuizen, Numrah Fadra, Sandra E Peterson, Susan A Lagerstedt, Laura J Train, Linnea M Baudhuin, Eric W Klee, Matthew J Ferber, Suzette J Bielinski, Pedro J Caraballo, Richard M Weinshilboum, and John L Black.
• Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
• J Mol Diagn. 2016 May 1; 18 (3): 438-445.

AbstractSignificant barriers, such as lack of professional guidelines, specialized training for interpretation of pharmacogenomics (PGx) data, and insufficient evidence to support clinical utility, prevent preemptive PGx testing from being widely clinically implemented. The current study, as a pilot project for the Right Drug, Right Dose, Right Time-Using Genomic Data to Individualize Treatment Protocol, was designed to evaluate the impact of preemptive PGx and to optimize the workflow in the clinic setting. We used an 84-gene next-generation sequencing panel that included SLCO1B1, CYP2C19, CYP2C9, and VKORC1 together with a custom-designed CYP2D6 testing cascade to genotype the 1013 subjects in laboratories approved by the Clinical Laboratory Improvement Act. Actionable PGx variants were placed in patient's electronic medical records where integrated clinical decision support rules alert providers when a relevant medication is ordered. The fraction of this cohort carrying actionable PGx variant(s) in individual genes ranged from 30% (SLCO1B1) to 79% (CYP2D6). When considering all five genes together, 99% of the subjects carried an actionable PGx variant(s) in at least one gene. Our study provides evidence in favor of preemptive PGx testing by identifying the risk of a variant being present in the population we studied.Copyright © 2016 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

17 keywords...

hide…